[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
1999, Volume 29, Number 2, Page(s) 74-81
[ Summary ]
I-131 Meta-iodobenzylguanidine and other diagnostic methods in neuroblastoma
BETÜL ULUKOL1, SEVGİ GÖZDAŞOĞLU1, HİKMET BAYHAN2, EMEL ÖZTÜRK2, EMEL ÜNAL1, GÜLSAN YAVUZ1, CEMİL EKİNCİ3, ÖMER ULUOĞLU4, HALUK GÖKÇORA5
Departments of 1Pediatric Hematology-Oncology, 3Pathology and 5Pediatric Surgery, Ankara University Medical School, Ankara-Turkey
2Department of Nuclear Medicine, Gülhane Military Medical Academy, Ankara-Turkey
4Department of Pathology, Gazi University Medical School, Ankara-Turkey

The aim of this study was to evaluate the correlation between I-131 meta-iodobenzylguanidine scintigraphy, urinary vanillylmandelic acid levels and Tc-99m methylene diphosphonic acid bone scintigraphy in the diagnosis of neuroblastoma. We assessed the results of I-131 meta-iodobenzylguanidine used for differential diagnosis and follow-up of 16 children with solid tumors. I-131 meta-iodobenzylguanidine was used for differential diagnosis in 15 patients, for re-evaluation following the treatment in four and for evaluation of the treatment in one patient. I-131 meta-iodobenzylguanidine scintigraphy yielded pathologic findings in all patients with neuroblastoma and was normal in other patients. The sensitivity and specificity of I-131 meta-iodobenzylguanidine scintigraphy was 100% for the diagnosis of neuroblastoma patients. The urinary vanillylmandelic acid levels were high in only two of the 10 patients with neuroblastoma. Tc-99m methylene diphosphonic acid bone scintigraphy was performed in 13 patients with solid tumor and found to be pathologic in 8 patients with neuroblastoma.

[ Summary ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]